TREATMENT OF HEPATITIS C VIRUS IN UNDERSERVED POPULATIONS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们建议进行一项研究，以评估为吸毒者治疗丙型肝炎的可行性。我们假设，通过最大限度地增加促进因素并最大限度地减少治疗障碍，我们可以使吸毒者接受有效的丙型肝炎治疗。具体目标是： 1.估计从社区现场研究中心转诊接受丙型肝炎治疗评价的药物使用比例，这些患者（a）完成了丙型肝炎治疗的医学评价，（B）接受了丙型肝炎抗病毒治疗，（c）完成了丙型肝炎抗病毒治疗。 2.描述与完成这些结果相关的吸毒者特征。 3.为了确定（即，定性和定量描述）未开始治疗和治疗中止的原因。 4.描述聚乙二醇干扰素和利巴韦林方案在活跃药物使用者中的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose to conduct a study to assess the feasibility of treating drug users for hepatitis C. We hypothesize that by maximizing facilitators and minimizing barriers to treatment we can enable drug users to receive effective treatment for hepatitis C. The specific aims are: 1. To estimate the proportions of drug uses referred from community-based field sites presenting for evaluation for hepatitis C treatment who (a) complete a medical evaluation for hepatitis C treatment, (b) receive antiviral treatment for hepatitis C, and (c) complete antiviral treatment for hepatitis C. 2. To describe the characteristics of drug users associated with completion of these outcomes. 3. To determine (i.e., describe qualitively and quantify) reasons for not starting treatment and for treatment discontinuation. 4. To describe the safety and efficacy of the pegylated interferon and ribavirin regimen in active drug users.